LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Landon C. Brown, Matthew D. Tucker, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew K. Labriola, Rajan T. Gupta, Daniele Marin, Yuan Wu, Santosh Gupta, Tian Zhang, Michael R. Harrison, Daniel J. George, Ajjai Alva, Emmanuel S. Antonarakis, Andrew J. Armstrong

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types'. Together they form a unique fingerprint.

Medicine & Life Sciences